Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

TCD17197 (R/R AML)

Clinical study of safety and efficacy of the study drug SAR443579 in patients with leukemia.
Who can enter
  • Children with relapsed or refractory (not responding to therapy) acute myeloid leukemia (R/R AML)
  • Age: 12 years and older


The goal of this study is to research the safety and efficacy of the study drug SAR443579 in patients with relapsed or refractory acute myeloid leukemia (R/R AML).


The drug that is being studied in this research, SAR443579, is an immunotherapy. SAR443579 is a molecule that is similar to an antibody. An antibody is a protein that is produced in the blood to combat diseases by attacking and destroying harmful cells and organisms such as bacteria and viruses.

SAR443579 is designed to bind the CD123 protein, produced by certain cancer cells, with one side of the molecule. The other side reacts with a protein that is produced by certain immune cells. Binding of a SAR443579 molecule to both cancer cell and immune cell may lead to activation of the immune cell, resulting in killing the cancer cells that produce CD123.

Research with laboratory animals with AML has shown that SAR443579 can have an effect on the progression of the disease.


In order to participate in a study please refer to your/your child’s doctor.
For international patients: please feel welcome to contact our International Office.

Last reviewed

July 21, 2023